1. Home
  2. LIF vs ACAD Comparison

LIF vs ACAD Comparison

Compare LIF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Life360 Inc.

LIF

Life360 Inc.

HOLD

Current Price

$46.37

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.08

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIF
ACAD
Founded
2008
1993
Country
United States
United States
Employees
547
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
LIF
ACAD
Price
$46.37
$22.08
Analyst Decision
Strong Buy
Buy
Analyst Count
11
22
Target Price
$75.58
$30.55
AVG Volume (30 Days)
832.9K
1.3M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
N/A
$726,437,000.00
Revenue This Year
$36.21
$18.80
Revenue Next Year
$20.80
$11.70
P/E Ratio
$425.29
$9.53
Revenue Growth
N/A
40.45
52 Week Low
$37.01
$14.45
52 Week High
$112.54
$28.35

Technical Indicators

Market Signals
Indicator
LIF
ACAD
Relative Strength Index (RSI) 54.98 50.23
Support Level $37.41 $21.51
Resistance Level $47.43 $22.91
Average True Range (ATR) 2.12 0.61
MACD 0.21 0.04
Stochastic Oscillator 58.78 59.02

Price Performance

Historical Comparison
LIF
ACAD

About LIF Life360 Inc.

Life360 is the world's largest family focused social network, with nearly 100 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: